“A ‘breakthrough’ drug that gives extra months of life to men with advanced prostate cancer has been rejected for use on the NHS.
The once-daily pill was developed by UK scientists at the Institute of Cancer Research (ICR) and trials were partly funded by British charities.
But it has been branded as too expensive by the rationing watchdog the National Institute for Health and Clinical Excellence.
Abiraterone is the latest prostate cancer drug to face an NHS ban despite being proven to extend life for men with advanced disease. Last month another drug – Jevtana – was turned down as ‘not cost-effective’.
It is a fresh blow for doctors and patients who hoped a new era of drugs could lessen the deadly toll of prostate cancer, which has been described in the past as a low-profile ‘Cinderella’ disease.”